Stock Track | Alumis Inc. Plunges 5.79% Post-Market Following $175 Million Public Stock Offering Announcement

Stock Track

01/07

Alumis Inc. (ALMS) saw its shares plummet 5.79% in post-market trading on Tuesday, reversing earlier gains driven by positive clinical trial results.

The decline followed the company's announcement of a proposed public offering of $175 million in common stock, with an additional $26.25 million overallotment option for underwriters. Such offerings often lead to share price declines due to dilution concerns among existing shareholders.

Earlier in the day, Alumis had surged after reporting successful Phase 3 trials for its plaque psoriasis treatment, envudeucitinib. However, the subsequent capital-raising plans appear to have overshadowed this positive development in after-hours trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1105811410"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105811410\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105811410?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105811410","market":"nz","top_or_hot":-1,"title":"Stock Track | Alumis Inc. Plunges 5.79% Post-Market Following $175 Million Public Stock Offering Announcement","media":"Stock Track","content":"<p>Alumis Inc. (ALMS) saw its shares plummet 5.79% in post-market trading on Tuesday, reversing earlier gains driven by positive clinical trial results.</p><p>The decline followed the company's announcement of a proposed public offering of $175 million in common stock, with an additional $26.25 million overallotment option for underwriters. Such offerings often lead to share price declines due to dilution concerns among existing shareholders.</p><p>Earlier in the day, Alumis had surged after reporting successful Phase 3 trials for its plaque psoriasis treatment, envudeucitinib. However, the subsequent capital-raising plans appear to have overshadowed this positive development in after-hours trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alumis Inc. Plunges 5.79% Post-Market Following $175 Million Public Stock Offering Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alumis Inc. Plunges 5.79% Post-Market Following $175 Million Public Stock Offering Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-07 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alumis Inc. (ALMS) saw its shares plummet 5.79% in post-market trading on Tuesday, reversing earlier gains driven by positive clinical trial results.</p><p>The decline followed the company's announcement of a proposed public offering of $175 million in common stock, with an additional $26.25 million overallotment option for underwriters. Such offerings often lead to share price declines due to dilution concerns among existing shareholders.</p><p>Earlier in the day, Alumis had surged after reporting successful Phase 3 trials for its plaque psoriasis treatment, envudeucitinib. However, the subsequent capital-raising plans appear to have overshadowed this positive development in after-hours trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"","article_id":"1105811410","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105811410","pubTimestamp":1767747776,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Alumis Inc. (ALMS) saw its shares plummet 5.79% in post-market trading on Tuesday, reversing earlier gains driven by positive clinical trial results.The decline followed the company's announcement of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc."},"translate_title":"股票追踪|Alumis Inc.宣布1.75亿美元公开发行股票后盘后暴跌5.79%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1},"content_text":"Alumis Inc. (ALMS) saw its shares plummet 5.79% in post-market trading on Tuesday, reversing earlier gains driven by positive clinical trial results.The decline followed the company's announcement of a proposed public offering of $175 million in common stock, with an additional $26.25 million overallotment option for underwriters. Such offerings often lead to share price declines due to dilution concerns among existing shareholders.Earlier in the day, Alumis had surged after reporting successful Phase 3 trials for its plaque psoriasis treatment, envudeucitinib. However, the subsequent capital-raising plans appear to have overshadowed this positive development in after-hours trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}